Go to content
UR Home

Cabozantinib for HCC Treatment, From Clinical Back to Experimental Models

URN to cite this document:
urn:nbn:de:bvb:355-epub-515258
DOI to cite this document:
10.5283/epub.51525
Deng, Shanshan ; Solinas, Antonio ; Calvisi, Diego F.
[img]
Preview
License: Creative Commons Attribution 4.0
PDF - Published Version
(3MB)
Date of publication of this fulltext: 27 Jan 2022 12:42


Abstract

Hepatocellular carcinoma (HCC) is the fourth leading cause of cancer-related mortality worldwide. Patients with early-stage HCC can be treated successfully with surgical resection or liver transplantation. However, the usual late diagnosis of HCC precludes curative treatments, and systemic therapies are the only viable option for inoperable patients. Sorafenib, an orally available multikinase ...

plus


Owner only: item control page
  1. Homepage UR

University Library

Publication Server

Contact:

Publishing: oa@ur.de
0941 943 4239

Dissertations: dissertationen@ur.de
0941 943 3904

Research data: daten@ur.de
0941 943 4239

Contact persons